Latest & greatest articles for heparin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heparin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on heparin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for heparin

61. Bivalirudin vs Heparin With or Without Tirofiban During Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction: The BRIGHT Randomized Clinical Trial.

Bivalirudin vs Heparin With or Without Tirofiban During Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction: The BRIGHT Randomized Clinical Trial. 25775052 2015 04 08 2015 06 18 2016 11 25 1538-3598 313 13 2015 Apr 07 JAMA JAMA Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial. 1336-46 10.1001/jama.2015.2323 The safety and efficacy of bivalirudin compared (...) with heparin with or without glycoprotein IIb/IIIa inhibitors in patients with acute myocardial infarction (AMI) undergoing primary percutaneous coronary intervention (PCI) are uncertain. To determine if bivalirudin is superior to heparin alone and to heparin plus tirofiban during primary PCI. Multicenter, open-label trial involving 2194 patients with AMI undergoing primary PCI at 82 centers in China between August 2012 and June 2013. Patients were randomly assigned to receive bivalirudin with a post-PCI

JAMA2015

63. Pediatric heparin-induced thrombocytopenia: prevalence, thrombotic risk, and application of the 4Ts scoring system

Pediatric heparin-induced thrombocytopenia: prevalence, thrombotic risk, and application of the 4Ts scoring system 25444534 2014 12 22 2015 03 19 2017 02 20 1097-6833 166 1 2015 Jan The Journal of pediatrics J. Pediatr. Pediatric heparin-induced thrombocytopenia: prevalence, thrombotic risk, and application of the 4Ts scoring system. 144-50 10.1016/j.jpeds.2014.09.017 S0022-3476(14)00845-2 To characterize heparin-induced thrombocytopenia (HIT) at a single pediatric center including (...) the prevalence and the accuracy of the 4Ts scoring system as a predictor of HIT. In this retrospective cohort study, we identified 155 consecutive patients <21 years old with sufficient data for 4Ts scoring. The 4Ts scoring system is a validated pretest tool in adults that predicts the likelihood of HIT using clinical features. Hospital-wide exposure to unfractionated and low molecular weight heparin was determined by querying the hospital pharmacy database. The majority of patients with suspected HIT (61.2

EvidenceUpdates2015 Full Text: Link to full Text with Trip Pro

64. Unfractionated Heparin and Low-Molecular-Weight Heparin

Unfractionated Heparin and Low-Molecular-Weight Heparin © 2013 Thrombosis Canada. Page 1 of 5 UNFRACTIONATED HEPARIN AND LOW-MOLECULAR-WEIGHT HEPARIN TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To aid practitioners in prescribing unfractionated heparin and low-molecular-weight heparins to patients. ABBREVIATIONS: ALT alanine aminotransferase aPTT activated partial thromboplastin time AST aspartate aminotransferase AT antithrombin CBC complete blood count HIT heparin (...) -induced thrombocytopenia INR international normalized ratio IV intravenous LMWH low-molecular-weight heparin MI myocardial infarction PT prothrombin time TNK tenecteplase tPA tissue plasminogen activator UFH unfractionated heparin U units VTE venous thromboembolism MECHANISM OF ACTION: Unfractionated heparin (UFH) acts as an anticoagulant by forming a complex with antithrombin (AT) catalysing the inhibition of several activated blood coagulation factors: thrombin (factor IIa), factor IXa, Xa, XIa

Thrombosis Interest Group of Canada2015

65. Association between the use of fondaparinux vs low-molecular-weight heparin and clinical outcomes in patients with non-ST-segment elevation myocardial infarction.

Association between the use of fondaparinux vs low-molecular-weight heparin and clinical outcomes in patients with non-ST-segment elevation myocardial infarction. IMPORTANCE: Fondaparinux was associated with reduced major bleeding events and improved survival compared with low-molecular-weight heparin (LMWH) in a large randomized clinical trial involving patients with non-ST-segment elevation myocardial infarction (NSTEMI). Large-scale experience of the use of fondaparinux vs LMWH in a nontrial (...) setting is lacking. OBJECTIVE: To study the association between the use of fondaparinux vs LMWH and outcomes in patients with NSTEMI in Sweden. DESIGN, SETTING, AND PATIENTS: Prospective multicenter cohort study from the Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies registry involving 40,616 consecutive patients with NSTEMI who received fondaparinux or LMWH between September 1, 2006, through June 30, 2010

JAMA2015 Full Text: Link to full Text with Trip Pro

66. PROPATEN heparin-bonded vascular graft for peripheral arterial disease

PROPATEN heparin-bonded vascular graft for peripheral arterial disease PR PROP OPA ATEN heparin-bonded vascular gr TEN heparin-bonded vascular graft for aft for peripher peripheral arterial disease al arterial disease Medtech innovation briefing Published: 13 October 2015 nice.org.uk/guidance/mib42 pathways Summary Summary The Gore PROPATEN heparin-bonded vascular graft is a synthetic graft used to treat peripheral arterial disease by bypassing damaged blood vessels. The graft is made from (...) expanded polytetrafluoroethylene (ePTFE) that has a layer of heparin anticoagulant bonded to its inner surface, which is designed to reduce graft occlusion. Relevant evidence was limited and consisted of 1 randomised controlled trial and 5 cohort studies, with either artificial graft or autologous vein graft comparators. The reports indicate that the PROPATEN graft is either equivalent or inferior to autologous vein grafts in maintaining patency (that is, remaining open and functional over time

National Institute for Health and Clinical Excellence - Advice2015

67. Randomized Phase III Trial of Standard Therapy Plus Low Molecular Weight Heparin in Patients With Lung Cancer: FRAGMATIC Trial

Randomized Phase III Trial of Standard Therapy Plus Low Molecular Weight Heparin in Patients With Lung Cancer: FRAGMATIC Trial 26700124 2016 02 03 2016 06 09 2016 11 22 1527-7755 34 5 2016 Feb 10 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Randomized Phase III Trial of Standard Therapy Plus Low Molecular Weight Heparin in Patients With Lung Cancer: FRAGMATIC Trial. 488-94 10.1200/JCO.2015.64.0268 Venous thromboembolism (VTE (...) ) is common in cancer patients. Evidence has suggested that low molecular weight heparin (LMWH) might improve survival in patients with cancer by preventing both VTE and the progression of metastases. No trial in a single cancer type has been powered to demonstrate a clinically significant survival difference. The aim of this trial was to investigate this question in patients with lung cancer. We conducted a multicenter, open-label, randomized trial to evaluate the addition of a primary prophylactic dose

EvidenceUpdates2015 Full Text: Link to full Text with Trip Pro

68. Randomised controlled trial: Low-molecular-weight heparin offers no benefit to patients with unexplained recurrent miscarriage in future pregnancy

Randomised controlled trial: Low-molecular-weight heparin offers no benefit to patients with unexplained recurrent miscarriage in future pregnancy Low-molecular-weight heparin offers no benefit to patients with unexplained recurrent miscarriage in future pregnancy | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username (...) * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Low-molecular-weight heparin offers no benefit to patients with unexplained recurrent miscarriage in future pregnancy Article Text Therapeutics/Prevention Randomised controlled trial Low-molecular-weight heparin offers no benefit to patients

Evidence-Based Medicine (Requires free registration)2015

69. Nebulized Heparin for Adjunctive Treatment of Mechanically Ventilated Patients in the ICU

Nebulized Heparin for Adjunctive Treatment of Mechanically Ventilated Patients in the ICU "Nebulized Heparin for Adjunctive Treatment of Mechanically Ventilated " by Phoebe Robinson < > > > > > Title Author Date of Award Summer 8-8-2015 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Mark Pedemonte, MD Second Advisor Annjanette Sommers, PA-C, MS Rights . Abstract Background: Acute lung injury (ALI) is a serious clinical concern brought (...) on by inflammatory triggers and is characterized by rapid onset of respiratory distress in the setting of inflammatory insult. Fibrin deposition from the inflammation leads to poor ventilation and perfusion. There is no current treatment for ALI other than supportive measures. Heparin is an anticoagulant that prevents fibrin deposition. Previous animal and ALI model studies have demonstrated improvement in lung function markers with nebulized heparin. This review looks at the effects of nebulized heparin

Pacific University EBM Capstone Project2015

70. Optimal Duration of Low Molecular Weight Heparin for the Treatment of Cancer-Related Deep Vein Thrombosis: The Cancer-DACUS Study

Optimal Duration of Low Molecular Weight Heparin for the Treatment of Cancer-Related Deep Vein Thrombosis: The Cancer-DACUS Study 25267738 2014 11 08 2015 03 20 2015 07 16 1527-7755 32 32 2014 Nov 10 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis: the Cancer-DACUS Study. 3607-12 10.1200/JCO.2013.51.7433 We evaluated the role (...) of residual vein thrombosis (RVT) to assess the optimal duration of anticoagulants in patients with cancer who have deep vein thrombosis (DVT) of the lower limbs. Patients with active cancer and a first episode of DVT treated with low molecular weight heparin (LMWH) for 6 months were eligible. Patients were managed according to RVT findings: those with RVT were randomly assigned to continue LMWH for an additional 6 months (group A1) or to discontinue it (group A2), and patients without RVT stopped LMWH

EvidenceUpdates2014 Full Text: Link to full Text with Trip Pro

71. Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients.

Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients. 25362228 2014 11 26 2014 12 15 2016 10 17 1538-3598 312 20 2014 Nov 26 JAMA JAMA Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients. 2135-45 10.1001/jama.2014.15101 Venous thromboembolism (VTE) is a common complication of acute illness, and its prevention is a ubiquitous aspect (...) of inpatient care. A multicenter blinded, randomized trial compared the effectiveness of the most common pharmocoprevention strategies, unfractionated heparin (UFH) and the low-molecular-weight heparin (LMWH) dalteparin, finding no difference in the primary end point of leg deep-vein thrombosis but a reduced rate of pulmonary embolus and heparin-induced thrombocytopenia among critically ill medical-surgical patients who received dalteparin. To evaluate the comparative cost-effectiveness of LMWH vs UFH for

JAMA2014

72. Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients.

Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients. IMPORTANCE: Venous thromboembolism (VTE) is a common complication of acute illness, and its prevention is a ubiquitous aspect of inpatient care. A multicenter blinded, randomized trial compared the effectiveness of the most common pharmocoprevention strategies, unfractionated heparin (UFH) and the low-molecular-weight heparin (LMWH) dalteparin, finding no (...) difference in the primary end point of leg deep-vein thrombosis but a reduced rate of pulmonary embolus and heparin-induced thrombocytopenia among critically ill medical-surgical patients who received dalteparin. OBJECTIVE: To evaluate the comparative cost-effectiveness of LMWH vs UFH for prophylaxis against VTE in critically ill patients. DESIGN, SETTING, AND PARTICIPANTS: Prospective economic evaluation concurrent with the Prophylaxis for Thromboembolism in Critical Care Randomized Trial (May 2006

JAMA2014

73. Slow versus fast subcutaneous heparin injections for prevention of bruising and site-pain intensity.

Slow versus fast subcutaneous heparin injections for prevention of bruising and site-pain intensity. BACKGROUND: Heparin is an anticoagulant medication that is normally injected subcutaneously. Subcutaneous administration of heparin may result in complications such as bruising, haematoma and pain at the injection site. One of the factors that may affect pain, haematoma and bruising is injection speed. OBJECTIVES: To assess the effects of the duration (speed) of subcutaneous heparin injection (...) on pain, haematoma and bruising at the injection site in people admitted to hospitals or clinics who require treatment with unfractionated heparin or low molecular weight heparin. SEARCH METHODS: The Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator searched the Specialised Register (last searched August 2013) and CENTRAL (2013, Issue 7). We searched MEDLINE, EMBASE, CINAHL and two Persian databases Iranmedex and SID (August 2013). SELECTION CRITERIA: We sought randomised

Cochrane2014

74. Heparin versus normal saline for patency of arterial lines.

Heparin versus normal saline for patency of arterial lines. BACKGROUND: For most patients who require intensive care, the success of clinical decision making and interventions is dependent on the accuracy of different physiological variables measured or obtained from samples using an arterial catheter. Maintaining the patency of these catheters is therefore essential for obtaining accurate measures, minimizing patient discomfort and reducing expenses incurred when an occluded catheter requires (...) replacement. Uncertainty exists amongst clinicians as to best practice surrounding the contents of the arterial catheter flush solution (heparin or saline). The use of heparin is more expensive and is accompanied by significant risks such as haemorrhage, hypersensitivity and heparin-induced thrombocytopenia (HIT). OBJECTIVES: The objective of this review was to evaluate whether normal saline is as efficacious and safe as heparin in maintaining the patency of arterial intravascular catheters in adult

Cochrane2014

75. Portable pneumatic compression versus low-molecular-weight heparin for prevention of deep vein thrombosis after lower-extremity joint arthroplasty

Portable pneumatic compression versus low-molecular-weight heparin for prevention of deep vein thrombosis after lower-extremity joint arthroplasty Portable pneumatic compression versus low-molecular-weight heparin for prevention of deep vein thrombosis after lower-extremity joint arthroplasty Portable pneumatic compression versus low-molecular-weight heparin for prevention of deep vein thrombosis after lower-extremity joint arthroplasty Record Status This is a bibliographic record (...) of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Portable pneumatic compression versus low-molecular-weight heparin for prevention of deep vein thrombosis after lower-extremity joint arthroplasty. Lansdale: HAYES, Inc.. Healthcare Technology Brief Publication. 2014 Authors' conclusions Deep vein thrombosis (DVT) is a blood clot, or thrombus, that forms in a deep vein most commonly in the legs. DVT is serious since

Health Technology Assessment (HTA) Database.2014

76. Low molecular weight heparin for prevention of central venous catheterization-related thrombosis in children.

Low molecular weight heparin for prevention of central venous catheterization-related thrombosis in children. BACKGROUND: The prevalence of children diagnosed with deep vein thrombosis or pulmonary embolism has been increasing in the last decade. The most common thrombosis risk factor in neonates, infants and children is the placement of a central venous catheter (CVC). To date, it is unknown if the practice of anticoagulation prophylaxis with low molecular weight heparin (LMWH) decreases CVC (...) -related thrombosis in children. OBJECTIVES: The primary objective of this review was to determine the effect of LMWH prophylaxis on reducing the incidence of CVC-related thrombosis in children.Secondary objectives were to determine the effect of LMWH on occlusion of CVCs, number of days of CVC patency, episodes of catheter-related sepsis, side effects of LMWH (allergic reactions, major and minor bleeding complications, abnormal coagulation profile, osteoporosis) and mortality during therapy. SEARCH

Cochrane2014

77. Low-molecular weight heparins versus warfarin for the long-term prevention or treatment of deep vein thrombosis or pulmonary embolism: a review of the clinical and cost-effectiveness

Low-molecular weight heparins versus warfarin for the long-term prevention or treatment of deep vein thrombosis or pulmonary embolism: a review of the clinical and cost-effectiveness Low-molecular weight heparins versus warfarin for the long-term prevention or treatment of deep vein thrombosis or pulmonary embolism: a review of the clinical and cost-effectiveness Low-molecular weight heparins versus warfarin for the long-term prevention or treatment of deep vein thrombosis or pulmonary (...) embolism: a review of the clinical and cost-effectiveness CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Low-molecular weight heparins versus warfarin for the long-term prevention or treatment of deep vein thrombosis or pulmonary embolism: a review of the clinical and cost-effectiveness. Ottawa: Canadian Agency for Drugs and Technologies

Health Technology Assessment (HTA) Database.2014

78. Low molecular weight heparins versus unfractionated heparin for thromboprophylaxis in surgery, cancer and general medicine: a review of the cost-effectiveness and safety

Low molecular weight heparins versus unfractionated heparin for thromboprophylaxis in surgery, cancer and general medicine: a review of the cost-effectiveness and safety Low molecular weight heparins versus unfractionated heparin for thromboprophylaxis in surgery, cancer and general medicine: a review of the cost-effectiveness and safety Low molecular weight heparins versus unfractionated heparin for thromboprophylaxis in surgery, cancer and general medicine: a review of the cost-effectiveness (...) and safety CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Low molecular weight heparins versus unfractionated heparin for thromboprophylaxis in surgery, cancer and general medicine: a review of the cost-effectiveness and safety. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary

Health Technology Assessment (HTA) Database.2014

79. Low molecular weight heparins versus new oral anticoagulants for long-term thrombosis prophylaxis and long-term treatment of DVT and PE: a review of the clinical and cost-effectiveness

Low molecular weight heparins versus new oral anticoagulants for long-term thrombosis prophylaxis and long-term treatment of DVT and PE: a review of the clinical and cost-effectiveness Low molecular weight heparins versus new oral anticoagulants for long-term thrombosis prophylaxis and long-term treatment of DVT and PE: a review of the clinical and cost-effectiveness Low molecular weight heparins versus new oral anticoagulants for long-term thrombosis prophylaxis and long-term treatment of DVT (...) and PE: a review of the clinical and cost-effectiveness CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Low molecular weight heparins versus new oral anticoagulants for long-term thrombosis prophylaxis and long-term treatment of DVT and PE: a review of the clinical and cost-effectiveness. Ottawa: Canadian Agency for Drugs

Health Technology Assessment (HTA) Database.2014

80. Improving clinical interpretation of the anti-platelet factor 4/heparin enzyme-linked immunosorbent assay for the diagnosis of heparin-induced thrombocytopenia through the use of receiver operating characteristic analysis, stratum-specific likelihood rati

Improving clinical interpretation of the anti-platelet factor 4/heparin enzyme-linked immunosorbent assay for the diagnosis of heparin-induced thrombocytopenia through the use of receiver operating characteristic analysis, stratum-specific likelihood rati 23703622 2013 10 01 2014 01 06 2013 10 01 1931-3543 144 4 2013 Oct Chest Chest Improving clinical interpretation of the anti-platelet factor 4/heparin enzyme-linked immunosorbent assay for the diagnosis of heparin-induced thrombocytopenia (...) through the use of receiver operating characteristic analysis, stratum-specific likelihood ratios, and Bayes theorem. 1269-75 10.1378/chest.12-2712 Heparin-induced thrombocytopenia (HIT) is diagnosed using clinical criteria and detection of platelet-activating anti-platelet factor 4/heparin (anti-PF4/H) antibodies, usually through a surrogate enzyme-linked immunosorbent assay (ELISA). The high false-positive rate (FPR) of this ELISA prompted us to reexamine its interpretation. We analyzed anti-PF4/H

EvidenceUpdates2014